Cargando…

Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: a 12-year experience

BACKGROUND: Invasive fungal diseases (IFD) are an important cause of morbidity and mortality in immunocompromised patients, and early diagnosis and management are a challenge. We evaluated the clinical utility of computed tomography (CT)-guided percutaneous lung biopsies in diagnosing IFD. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Lass-Flörl, Cornelia, Aigner, Maria, Nachbaur, David, Eschertzhuber, Stephan, Bucher, Brigitte, Geltner, Christian, Bellmann, Romuald, Lackner, Michaela, Orth-Höller, Dorothea, Würzner, Reinhard, Weiss, Günter, Glodny, Bernhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696440/
https://www.ncbi.nlm.nih.gov/pubmed/28956284
http://dx.doi.org/10.1007/s15010-017-1072-6
_version_ 1783280451635380224
author Lass-Flörl, Cornelia
Aigner, Maria
Nachbaur, David
Eschertzhuber, Stephan
Bucher, Brigitte
Geltner, Christian
Bellmann, Romuald
Lackner, Michaela
Orth-Höller, Dorothea
Würzner, Reinhard
Weiss, Günter
Glodny, Bernhard
author_facet Lass-Flörl, Cornelia
Aigner, Maria
Nachbaur, David
Eschertzhuber, Stephan
Bucher, Brigitte
Geltner, Christian
Bellmann, Romuald
Lackner, Michaela
Orth-Höller, Dorothea
Würzner, Reinhard
Weiss, Günter
Glodny, Bernhard
author_sort Lass-Flörl, Cornelia
collection PubMed
description BACKGROUND: Invasive fungal diseases (IFD) are an important cause of morbidity and mortality in immunocompromised patients, and early diagnosis and management are a challenge. We evaluated the clinical utility of computed tomography (CT)-guided percutaneous lung biopsies in diagnosing IFD. METHODS: Between 2003 and 2014, we analyzed 2671 CT-guided lung biopsies, from which 157 were IFD associated; we aimed to determine microbiological-based diagnostic accuracy of calcofluor white staining (CFWS), culture, Aspergillus antigen detection (GM), broad-range fungal PCR, and Aspergillus PCR per sample. RESULTS: 127 (81%) specimens were microscopically positive for any fungal elements, 30 (19%) negative. Aspergillus and non-Aspergillus like hyphae were obtained in 85 (67%) and 42 (33%) specimens, respectively. CFWS positivity was defined as proof of infection. Sensitivity, specificity, and positive (PPV) and negative predictive (NPV) values for CT scan were 100, 44, 80, and 100%, for Aspergillus PCR 89, 58, 88, and 58%, for broad-range fungal PCR 90, 83, 95, and 90%, and for GM 94, 83, 95, and 90%. The most common CT features were patchy opacifications with central necrosis (78%) or cavern defects (50%), less common were air bronchograms (39%) or ground glass halos (39%), and all other features were rare. The overall pneumothorax rate subsequent to biopsy was 19%, but in only 2% of all cases the placement of a chest tube was indicated. One case of fatal air embolism occurred. CONCLUSIONS: CT-guided lung biopsies have high diagnostic accuracy in terms of microscopic examination, and complication rates are low. Molecular-based and antigen tests applied on fungal hyphae-positive specimens showed comparable results.
format Online
Article
Text
id pubmed-5696440
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-56964402017-11-30 Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: a 12-year experience Lass-Flörl, Cornelia Aigner, Maria Nachbaur, David Eschertzhuber, Stephan Bucher, Brigitte Geltner, Christian Bellmann, Romuald Lackner, Michaela Orth-Höller, Dorothea Würzner, Reinhard Weiss, Günter Glodny, Bernhard Infection Original Paper BACKGROUND: Invasive fungal diseases (IFD) are an important cause of morbidity and mortality in immunocompromised patients, and early diagnosis and management are a challenge. We evaluated the clinical utility of computed tomography (CT)-guided percutaneous lung biopsies in diagnosing IFD. METHODS: Between 2003 and 2014, we analyzed 2671 CT-guided lung biopsies, from which 157 were IFD associated; we aimed to determine microbiological-based diagnostic accuracy of calcofluor white staining (CFWS), culture, Aspergillus antigen detection (GM), broad-range fungal PCR, and Aspergillus PCR per sample. RESULTS: 127 (81%) specimens were microscopically positive for any fungal elements, 30 (19%) negative. Aspergillus and non-Aspergillus like hyphae were obtained in 85 (67%) and 42 (33%) specimens, respectively. CFWS positivity was defined as proof of infection. Sensitivity, specificity, and positive (PPV) and negative predictive (NPV) values for CT scan were 100, 44, 80, and 100%, for Aspergillus PCR 89, 58, 88, and 58%, for broad-range fungal PCR 90, 83, 95, and 90%, and for GM 94, 83, 95, and 90%. The most common CT features were patchy opacifications with central necrosis (78%) or cavern defects (50%), less common were air bronchograms (39%) or ground glass halos (39%), and all other features were rare. The overall pneumothorax rate subsequent to biopsy was 19%, but in only 2% of all cases the placement of a chest tube was indicated. One case of fatal air embolism occurred. CONCLUSIONS: CT-guided lung biopsies have high diagnostic accuracy in terms of microscopic examination, and complication rates are low. Molecular-based and antigen tests applied on fungal hyphae-positive specimens showed comparable results. Springer Berlin Heidelberg 2017-09-27 2017 /pmc/articles/PMC5696440/ /pubmed/28956284 http://dx.doi.org/10.1007/s15010-017-1072-6 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Paper
Lass-Flörl, Cornelia
Aigner, Maria
Nachbaur, David
Eschertzhuber, Stephan
Bucher, Brigitte
Geltner, Christian
Bellmann, Romuald
Lackner, Michaela
Orth-Höller, Dorothea
Würzner, Reinhard
Weiss, Günter
Glodny, Bernhard
Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: a 12-year experience
title Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: a 12-year experience
title_full Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: a 12-year experience
title_fullStr Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: a 12-year experience
title_full_unstemmed Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: a 12-year experience
title_short Diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: a 12-year experience
title_sort diagnosing filamentous fungal infections in immunocompromised patients applying computed tomography-guided percutaneous lung biopsies: a 12-year experience
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696440/
https://www.ncbi.nlm.nih.gov/pubmed/28956284
http://dx.doi.org/10.1007/s15010-017-1072-6
work_keys_str_mv AT lassflorlcornelia diagnosingfilamentousfungalinfectionsinimmunocompromisedpatientsapplyingcomputedtomographyguidedpercutaneouslungbiopsiesa12yearexperience
AT aignermaria diagnosingfilamentousfungalinfectionsinimmunocompromisedpatientsapplyingcomputedtomographyguidedpercutaneouslungbiopsiesa12yearexperience
AT nachbaurdavid diagnosingfilamentousfungalinfectionsinimmunocompromisedpatientsapplyingcomputedtomographyguidedpercutaneouslungbiopsiesa12yearexperience
AT eschertzhuberstephan diagnosingfilamentousfungalinfectionsinimmunocompromisedpatientsapplyingcomputedtomographyguidedpercutaneouslungbiopsiesa12yearexperience
AT bucherbrigitte diagnosingfilamentousfungalinfectionsinimmunocompromisedpatientsapplyingcomputedtomographyguidedpercutaneouslungbiopsiesa12yearexperience
AT geltnerchristian diagnosingfilamentousfungalinfectionsinimmunocompromisedpatientsapplyingcomputedtomographyguidedpercutaneouslungbiopsiesa12yearexperience
AT bellmannromuald diagnosingfilamentousfungalinfectionsinimmunocompromisedpatientsapplyingcomputedtomographyguidedpercutaneouslungbiopsiesa12yearexperience
AT lacknermichaela diagnosingfilamentousfungalinfectionsinimmunocompromisedpatientsapplyingcomputedtomographyguidedpercutaneouslungbiopsiesa12yearexperience
AT orthhollerdorothea diagnosingfilamentousfungalinfectionsinimmunocompromisedpatientsapplyingcomputedtomographyguidedpercutaneouslungbiopsiesa12yearexperience
AT wurznerreinhard diagnosingfilamentousfungalinfectionsinimmunocompromisedpatientsapplyingcomputedtomographyguidedpercutaneouslungbiopsiesa12yearexperience
AT weissgunter diagnosingfilamentousfungalinfectionsinimmunocompromisedpatientsapplyingcomputedtomographyguidedpercutaneouslungbiopsiesa12yearexperience
AT glodnybernhard diagnosingfilamentousfungalinfectionsinimmunocompromisedpatientsapplyingcomputedtomographyguidedpercutaneouslungbiopsiesa12yearexperience